Clinical Trial Detail

NCT ID NCT02393794
Title Romidepsin Plus Cisplatin in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)
Recruitment Suspended
Gender female
Phase Phase Ib/II
Variant Requirements No
Sponsors Priyanka Sharma
Indications

breast cancer

triple-receptor negative breast cancer

Therapies

Cisplatin + Nivolumab + Romidepsin

Cisplatin + Romidepsin

Age Groups: adult

No variant requirements are available.